A5047408762- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Advanced Breast Cancer Therapies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Chemotherapy-related skin toxicity
- Reproductive Biology and Fertility
- Breast Lesions and Carcinomas
- Hair Growth and Disorders
- Nasal Surgery and Airway Studies
- Cancer survivorship and care
- Cancer Risks and Factors
- Brain Metastases and Treatment
- Lung Cancer Treatments and Mutations
- Childhood Cancer Survivors' Quality of Life
- BRCA gene mutations in cancer
- Olfactory and Sensory Function Studies
- Helicobacter pylori-related gastroenterology studies
- Cancer, Hypoxia, and Metabolism
- Estrogen and related hormone effects
- Dupuytren's Contracture and Treatments
- Medication Adherence and Compliance
European Institute of Oncology
2016-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2019-2024
Ripamonti
2020-2022
MultiMedica
2017
International Breast Cancer Study Group
2017
Ospedale degli Infermi
2017
Fondazione Lanza
2011-2014
Preclinical and clinical studies suggest synergistic activity between somatostatin analogues mammalian target of rapamycin inhibitors. The safety everolimus was assessed in combination with octreotide long-acting repeatable (LAR) patients neuroendocrine tumors (NETs) gastroenteropancreatic lung origin.This a phase 2, multicenter trial using Simon's 2-stage minimax design. Treatment-naive advanced well-differentiated NETs tract origin received 10 mg daily, LAR 30 every 28 days. primary...
Abstract Cyclin-dependent kinase 12 (CDK12) overexpression is implicated in breast cancer, but whether it has a primary or only cooperative tumorigenic role unclear. Here, we show that transgenic CDK12 the mouse mammary gland per se sufficient to drive emergence of multiple and multifocal tumors, while, cooperation with known oncogenes, promotes earlier tumor onset metastasis. Integrative transcriptomic, metabolomic functional data reveal hyperactivation serine-glycine-one-carbon network...
Chemotherapy-induced alopecia (CIA) is a distressing side effect of cancer therapy. The trial aimed to assess feasibility and effectiveness scalp-cooling system DigniCap® prevent CIA in primary breast patients receiving an anthracycline containing adjuvant chemotherapy (CT). Hair loss (HL) was evaluated by patient self-assessment the physician according Dean's scale at baseline after each cycle CT. efficacy endpoint HL score least 3 weeks completing A 0–2 (i.e. ≤50%) considered success. From...
Few data are available outlining outcomes of panitumumab in advanced colorectal cancer patients benefiting from prior cetuximab-based regimens.Thirty with KRAS wild type metastatic clinical benefit regimens between May 2004 and October 2011 were reviewed at nine Italian Institutions. Inclusion key criteria included interruption cetuximab for reasons other than progressive disease. Patients classified according to (0 or ≥1), response stabilization, surgery metastases, Köhne prognostic score....
Invasive lobular carcinomas (ILCs) account for 10-15% of all breast cancers. They are characterized by an elevated endocrine responsiveness and a long lasting risk relapse over time. Here we report the first time analysis clinical pathological features associated with late distant recurrence in ILCs.We retrospectively analyzed consecutive patients hormone receptor-positive ILC operated at European Institute Oncology (EIO) between June 1994 December 2010 scheduled to receive least 5 years...
Adjuvant chemotherapy for Luminal B-like breast cancers usually includes anthracycline-based regimens. However, some patients are reluctant to receive because of side-effects, especially alopecia, and ask a "less intensive" or personalized approach.We conducted phase II feasibility trial evaluate pegylated liposomal doxorubicin (PLD, Caelyx®) as adjuvant chemotherapy. Patients who received surgery pT1-3, any N, luminal early-stage cancer (EBC) candidates were included. PLD was administered...
4136^ Background: Everolimus has shown antitumor activity in patients (pts) with advanced pancreatic neuroendocrine tumors (NETs). We aimed to assess efficacy and safety of everolimus combination octreotide long-acting repeatable (LAR) well differentiated NETs gastroenteropancreatic lung origin. Methods: performed a phase II, multicenter trial using Simon two-stage minmax design. Pts differentiated, previously untreated the tract received LAR 30 mg every 28 days conjunction 10 per day...
Incomplete response to neoadjuvant chemotherapy (NACT) in triple negative breast cancer (TNBC) patients is correlated high risk of relapse. This study aimed evaluate the role adjuvant TNBC with residual tumor after NACT.We retrospectively reviewed outcome at surgery a treatment, followed by either or observation. Primary endpoints were Disease Free Survival (DFS) and Overall (OS).Between January 2000 December 2016, 223 early operated European Institute Oncology eligible. A total 83.4 %...
PurposeAlthough younger age has been negatively associated with persistence to adjuvant endocrine therapy (ET), factors contributing non-persistence remain poorly understood. We assessed ET and described the 5-year trajectories of quality life (QoL) symptoms in young women (≤40 years) hormone receptor-positive breast cancer (BC).MethodsWe retrieved data on clinical characteristics from medical annual records European cohort "Helping Ourselves, Helping Others: The Young Women's BC Study"...
e15160 Background: We previously presented data about this phase II study showing that the combination of Everolimus and octreotide LAR in first line setting for advanced NETs, is an active a safe treatment. At medium follow-up 277 days, median time to progression (TTP) overall survival (OS) have not been reached (ASCO 2013 Abs. 4136). Methods: performed 2, multicenter trial using Simon two-stage minmax design. Patients with well differentiated, untreated NETs gastroenteropancreatic (GEP)...
Abstract Background The International Breast Cancer Study Group (IBCSG), in collaboration with Dana-Farber Institute, conducts the European (EU) cohort of Helping Ourselves Others (HOHO) study. HOHO is a prospective longitudinal study investigating short and long-term treatment fertility concerns young women breast cancer (BC): most previous studies have been retrospective. Patients methods From Aug 2009-Jan 2016, 300 patients aged 18-40 yrs early/advanced BC were enrolled within 6 mos...